



2007-09-17

PRESSRELEASE

Oasmia to NGM Equity

Oasmia Pharmaceutical is being listed on NGM Equity, Sweden on September 18th 2007. This provides private and institutional shareholders with a better place to trade in the company's shares.

Oasmia is now ready to move forward to provide financial institutions and large investors with an interesting, long term investment opportunity.

- Our product portfolio within oncology is very strong, and we are in the near future approaching the veterinary market with a revolutionary cancer therapy for dogs. The positive development means that Oasmia is becoming a more and more attractive investment opportunity and that the company will benefit from being listed on NGM Equity, says Julian Aleksov, CEO of Oasmia.

For more information and downloading of the Listing prospectus, please visit our website www.oasmia.com

More information is available at www.ngm.se or www.oasmia.com

Media contact: Maria Lundén +46 (0) 18 50 54 40 e-mail: info@oasmia.com

Oasmia Pharmaceutical is a pharmaceutical company that specialises in the treatment of severe diseases. A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase.